PRCC Antibody

What is PRCC and what are the standard applications for PRCC antibodies?

PRCC (Papillary Renal Cell Carcinoma translocation-associated) is a protein encoded by the PRCC gene that plays roles in cell cycle regulation through interaction with MAD2L2. PRCC antibodies are primarily used in the following applications:

PRCC has a calculated molecular weight of 52 kDa but is typically observed at approximately 66 kDa in Western blot analyses . For optimal results, it is recommended to validate antibody performance in each specific experimental system as sensitivity may be sample-dependent .

What is the cellular localization of PRCC and how should this inform antibody selection?

PRCC predominantly localizes in cell nuclei as confirmed by fluorescence microscopy studies . This nuclear localization should inform both antibody selection and experimental design. When selecting antibodies for immunofluorescence or immunohistochemistry applications:

• Choose antibodies validated for nuclear protein detection

• Consider fixation methods that preserve nuclear architecture

• Include appropriate nuclear counterstains (e.g., DAPI) for co-localization studies

PRCC has been found to interact with various pre-mRNA splicing factors including SC35, PRL1, and CDC5 , suggesting its involvement in nuclear processes related to RNA processing. When designing experiments to study PRCC's nuclear functions, researchers should consider antibodies raised against epitopes that remain accessible in the nuclear environment.

How can researchers validate PRCC antibody specificity for experimental applications?

Comprehensive validation of PRCC antibodies should include:

• Positive and negative control samples:

  • Positive controls: HeLa cells express detectable levels of PRCC

  • Negative controls: Knockdown validation using shRNA (validated sequences available: 5'-ccgggctggtgcttattatcaggatctcgagatcctgataataagcaccagctttttg-3' and 5'-ccggacaccagatcacatatcttatctcgagataagatatgtgatctggtgttttttg-3')

• Multiple detection methods:

  • Western blot analysis showing the expected molecular weight band (66 kDa)

  • Immunohistochemistry with appropriate cellular localization pattern

  • Signal reduction/elimination in PRCC-knockdown cells

• Cross-reactivity assessment:

  • Test antibody reactivity against species of interest (commercial antibodies have been verified for human samples, with some cross-reacting with mouse, rat, and other species)

For quantitative applications like diagnostic assays, researchers should establish standard curves using recombinant PRCC protein to determine detection limits and dynamic range.

How can PRCC antibodies be used to investigate PRCC's role in cancer development and progression?

PRCC has been implicated in multiple cancer types with distinct roles, requiring specific experimental approaches:

• In hepatocellular carcinoma (HCC) research:

  • PRCC is highly expressed in HCC tissues and correlates with poor prognosis

  • Use IHC with tissue microarrays to correlate PRCC expression with clinicopathological characteristics

  • AlgorithmS program of ImageScope software can be used to calculate histochemical scores

  • Median scores should be used to distinguish between high and low PRCC expression levels

• For studying DNA damage sensitivity:

  • PRCC influences cancer cell sensitivity to DNA damage through the JNK/ATM/ATR/ATF2 axis

  • Combine PRCC antibody detection with markers of DNA damage (γH2AX) and pathway components

  • Design experiments that compare DNA damage responses in cells with normal versus altered PRCC expression

• For tumor heterogeneity investigations:

  • High PRCC expression correlates with increased intratumoral heterogeneity (ITH) in HCC patients

  • Use multiplexed antibody approaches to simultaneously detect PRCC and markers of cellular heterogeneity

The following experimental design is recommended for investigating PRCC's role in cancer progression:

What methodological approaches are optimal for using PRCC antibodies in diagnostic applications?

PRCC shows potential as a diagnostic biomarker, particularly for hepatocellular carcinoma:

• Serum detection methodology:

  • PRCC concentration in patient sera can be measured using antibody-based ELISA methods

  • Cutoff value of 0.99 μg/ml has been established for HCC diagnosis

  • Sensitivity (84%) and specificity (83%) exceed those of traditional alpha-fetoprotein (AFP) for HCC diagnosis

• Tissue diagnostic approaches:

  • Immunohistochemistry on tissue sections using PRCC antibodies

  • Requires standardized scoring system (e.g., AlgorithmS program of ImageScope software)

  • Should be combined with clinical data for ROC analysis

• Validation protocol for diagnostic applications:

  • Multi-center cohort validation

  • Comparison with established biomarkers (e.g., AFP for HCC)

  • Correlation with clinical outcomes

For researchers developing PRCC-based diagnostic tests, the following performance characteristics from clinical studies provide important benchmarks:

How can PRCC antibodies be integrated into multiplexed imaging approaches to study tumor microenvironment?

Advanced multiplexed imaging approaches using PRCC antibodies can provide insights into tumor-immune interactions:

• Imaging mass cytometry (IMC) methodology:

  • Heavy metal-labeled antibodies including PRCC can be used for multiplexed tissue imaging

  • Protocol includes staining FFPE tissue with antibody cocktail in 0.5% BSA overnight at 4°C

  • Ir-Intercalator staining (1:600 dilution) for 30 min at room temperature

  • Imaging using systems like Hyperion Imaging Cytometer (Fluidigm)

• Data analysis approaches:

  • t-distributed stochastic neighborhood embedding (t-SNE) for visualizing multiplexed measurements

  • PhenoGraph algorithm for cell phenotype classification

  • Statistical analysis using R stat package Wilcoxon test and visualization with ggplot2

• Panel design considerations:

  • Include markers for tumor cells (PanCK), T cells (CD3, CD4, CD8), and macrophages (CD68)

  • Consider adding markers for signaling pathways affected by PRCC (e.g., JNK pathway components)

When designing multiplexed panels including PRCC antibodies, researchers should be aware of the significant differences in immune infiltration between papillary and clear cell RCC:

How do researchers address the challenge of distinguishing between PRCC subtypes using antibody-based methods?

Papillary renal cell carcinoma is heterogeneous with multiple subtypes that have distinct molecular and clinical characteristics:

The following table summarizes key markers that can be used alongside PRCC antibodies to distinguish PRCC subtypes:

What are the technical considerations when using PRCC antibodies to evaluate treatment response in experimental models?

When designing experiments to evaluate treatment response using PRCC antibodies:

• Baseline expression assessment:

  • Establish baseline PRCC expression in tumor models before treatment

  • Consider genetic manipulation to create models with varying PRCC expression levels

• Treatment response monitoring:

  • For immunotherapy studies, correlate PRCC expression with immune infiltration patterns

  • For targeted therapies (e.g., MET inhibitors for Type 1 PRCC), monitor changes in PRCC expression and signaling pathways

• Experimental design considerations:

  • Include appropriate controls (vehicle, isotype antibodies)

  • Use multiple detection methods (WB, IHC, IF) to confirm findings

  • Correlate antibody-based detection with functional assays (e.g., spheroid formation, metastasis)

Recent clinical trials that could inform experimental design include:

How can researchers optimize PRCC antibody protocols for challenging sample types?

When working with challenging sample types, researchers should consider:

• Formalin-fixed paraffin-embedded (FFPE) tissues:

  • Antigen retrieval is critical (method depends on specific antibody)

  • Longer primary antibody incubation may be necessary (e.g., overnight at 4°C)

  • Signal amplification systems may improve detection sensitivity

• Liquid biopsies (serum/plasma):

  • Validated for serum PRCC detection in hepatocellular carcinoma patients

  • Consider sample preparation (centrifugation speed, temperature) to minimize interfering factors

  • Use purified recombinant PRCC for standard curves

• Tissue microarrays:

  • Successfully used for PRCC expression analysis in 66 HCC patients

  • Consider tissue heterogeneity when designing arrays

  • Include internal control tissues

• Storage and stability considerations:

  • Most commercial PRCC antibodies are stored in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

  • Maintain at -20°C for stability (up to one year after shipment)

  • Aliquoting is often unnecessary for -20°C storage

For long-term experimental planning, researchers should note that PRCC antibodies with optimal performance characteristics include:

• Host species: Rabbit (for most validated antibodies)

• Clonality: Both monoclonal and polyclonal options available

• Purification method: Antigen affinity purification provides high specificity